BioXcel Therapeutics (BTAI) Tops Q2 EPS by 50c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q2 EPS of ($0.21), $0.50 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $1.1 million versus the consensus estimate of $662.5 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• Petco Health and Wellness (WOOF) Misses Q1 EPS by 6c
• Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours